Immunotherapy is new revolution in cancer fight

June 2, 2014 by Jean-Louis Santini

Immunotherapy has made great strides against cancers like melanoma that were once believed incurable, though scientists still do not understand why it works well in some cases but not others.

The technique, hailed as Science magazine's breakthrough of 2013, involves training the immune system to attack tumors.

In some cases, the approach disarms the tumor's defenses, in other cases it selects a patient's toughest , growing them in a lab and reinjecting them to bolster the body's assault on cancer.

"The beauty of this approach is that it is more selective ... and is producing durable and long-lasting remissions," said Steven O'Day, associate professor of medicine at the University of Southern California Keck school of Medicine.

According to research published late last year, 40 percent of patients with advanced who were treated with immunotherapy were showing no signs of cancer seven years later.

The results of three clinical trials released Monday at the American Society of Clinical Oncology in Chicago may bolster this number.

One of them, an early phase one study of patients with inoperable melanoma, led to an unprecedented median survival of three and a half years in a cancer that usually kills within about one year.

"This is truly revolutionary and now the treatments are getting so good in melanoma that we are seeing for the first time significant progress in very difficult to treat ," added O'Day.

Solid tumors are found in most cancers, including cervical cancer, which is the latest breakthrough in immunotherapy.

Researchers from the National Institutes of Health reported Monday that a new technique to lift immune cells from a tumor and then grow billions of them in the lab for reinfusion into the patient succeeded in two of nine patients.

The women, both in their late 30s, were given less than a year to live before they entered the trial, and had cancer throughout their bodies. They now show no signs of cancer—one for 22 months and the other more than a year after treatment.

But why it did not work in the other eight subjects remains a mystery that scientists are working hard to solve.

In the meantime, more studies are being launched on immunotherapy as a treatment for oral and anal cancers that, like , are caused by the human papillomavirus (HPV).

When it comes to melanoma, as well as kidney and lung cancer, a new kind of drug that blocks a protein called PD-1 has energized the field of research.

"PD-1 is arguably the most exciting breakthrough in cancer therapy in a decade," said Mark Schoenebaum, an analyst with ISI Group.

Pharmaceutical giants Bristol-Myers Squibb and Merck are among those racing to make drugs that will help the immune system recognize and attack .

Experts say the field of has a market potential of 35 billion dollars.

Explore further: New therapies harness power of the immune system against cancer

Related Stories

New therapies harness power of the immune system against cancer

June 2, 2014
New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments – used ...

Long-term results encouraging for combination immunotherapy for advanced melanoma

June 2, 2014
The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results—long-lasting with high survival rates—researchers report. First author ...

Immunotherapy shows promise against melanoma

June 2, 2014
By unleashing the immune system to attack skin cancer, researchers have made important strides against melanoma, according to the results of three clinical trials released Monday.

New therapy wipes out cervical cancer in two women

June 2, 2014
Aricca Wallace knew she was nearly out of time. For more than three years, she had suffered cramping and irregular bleeding, which her doctor thought was a side effect of her birth control implant, known as an intrauterine ...

One woman's cancer battle highlights promise of new treatment

May 8, 2014
Just over two years ago, Melinda Bachini decided she was done with chemotherapy to treat her cholangiocarcinoma—a rare cancer of the bile duct that runs from the liver to the intestines.

Biomarker identifies melanoma patients who may respond to immunotherapy MK-3475

April 7, 2014
Among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates, according to results presented here at the AACR Annual Meeting ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Scottingham
not rated yet Jun 03, 2014
Hell yes.

In 10-15 years time (hopefully) our reaction to getting cancer will be: Silly tumor, you die now!

By that point, the side-effects of the ramped up immune system will be the part that people will dread.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.